

Top-funded digital health companies offering lifestyle interventions for dementia prevention: Company overview and evidence analysis

Rasita Vinay^{1,2¶*}, Jonas Probst^{2¶}, Panitda Huynh², Mathias Schlögl³, Tobias Kowatsch^{2,4,5&}, Marcia Nißen^{2&}

¹ Institute of Biomedical Ethics and History of Medicine, University of Zurich, Zurich, Switzerland

² School of Medicine, University of St. Gallen, St. Gallen, Switzerland

³ Clinic Barmelweid, Aargau, Switzerland

⁴ Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland

⁵ Centre for Digital Health Interventions, Department of Management, Technology and Economics, ETH Zurich, Zurich, Switzerland

* Corresponding author

Email: rasita.vinay@ibme.uzh.ch (RV)

¶ These authors contributed equally to this article

& These authors contributed equally to this article

33 **Abstract**

34 **Background and objective**

35 Dementia prevention has been recognized as a top priority by public health authorities due to
36 the lack of disease modifying treatments. In this regard, digital dementia-preventive lifestyle
37 services (DDLs) emerge as potentially pivotal services, aiming to address modifiable risk
38 factors on a large scale. This study aims to identify the top-funded companies offering DDLs
39 globally and evaluate their clinical evidence to gain insights into the current state of the global
40 service landscape.

41 **Methods**

42 A systematic screening of two financial databases (Pitchbook and Crunchbase) was conducted.
43 Corresponding published clinical evidence was collected through a systematic literature review
44 and analyzed regarding study purpose, results, quality of results, and level of clinical evidence.

45 **Findings**

46 The ten top-funded companies offering DDLs received a total funding of EUR 128.52 million,
47 of which three companies collected more than 75%. Clinical evidence was limited due to only
48 nine eligible publications, small clinical subject groups, the absence of longitudinal study
49 designs, and no direct evidence of dementia prevention.

50 **Conclusion**

51 The study highlights the need for a more rigorous evaluation of DDLs effectiveness in today's
52 market. It serves as a starting point for further research in digital dementia prevention.

53

54

55 **Introduction**

56 According to the World Health Organization (WHO), more than 55 million people worldwide
57 currently suffer from dementia, and projections indicate a rise to 78 million in 2030 and a
58 staggering 139 million people in 2050 (1). With a global prevalence of 6.9% in the age group
59 above 65 years, dementia has become one of the leading causes of care dependence in old age
60 and the seventh leading cause of global deaths (1).

61 The social and economic effects of dementia are severe, where a person with dementia (PWD)
62 is significantly more likely to be hospitalized and have a substantially higher average length of
63 stay in hospitals (2). In 2019, dementia incurred an estimated global cost of over USD 1.3
64 trillion, translating to approximately USD 24,000 per PWD (1). Informal care provided by
65 family members, friends, and neighbors makes up almost 50% of total dementia-associated
66 costs (1). Caregivers are often referred to as “invisible second patients” as they have a higher
67 likelihood of experiencing depression and anxiety (3), along with an increased risk of
68 developing cardiovascular diseases (4) due to their caregiving duties. To address the social and
69 economic ramifications of dementia, modern societies must strengthen their capabilities of
70 dementia prevention by leveraging scalable and cost-effective approaches. Amid the global
71 demographic shift and increasing labor shortage in healthcare (5), digital health interventions
72 (DHIs) could play a central role in prevention and in delivering scalable, personalized, and
73 evidence-based interventions (6).

74 Since no effective treatments for dementia are available, prioritizing prevention strategies
75 becomes a public health priority. Although dementia risk is strongly correlated with age, studies
76 indicate that lifestyle significantly influences individuals’ susceptibility to developing the
77 condition later in life (7). Modifiable risk factors that directly influence dementia risk include,
78 among others, physical activity, diet, and cognitive training (8,9). It is estimated that 30% of all

79 Alzheimer's disease (AD) cases could be prevented through the targeted change of these
80 modifiable risk factors (10). The WHO confirms the important role of prevention by making
81 the capacity improvement of healthcare professionals for the proactive management of
82 modifiable risk factors a main target in its global action plan against dementia (11).

83 DHIs are part of the broader concept of Digital Health and pose new opportunities to bridge the
84 gap in care access and quality in health systems (12–14). They offer various benefits to all
85 actors in the system (14) and an increasing body of evidence in various disease domains
86 suggests positive effects of DHIs on costs and health outcomes (6).

87 Against the background of upcoming demand for digital dementia-preventive lifestyle services
88 (DDLs) and an increasing number of companies in the field of DHIs, this study aims to
89 comprehensively identify and analyze companies offering DDLs by answering the following
90 research questions:

91 RQ1. What are the globally top-funded digital dementia-preventive lifestyle services?

92 RQ2. What is the clinical evidence of the identified solutions?

93 **Materials and methods**

94 In this section, we present the methodologies of two studies we conducted against the research
95 questions. Following the procedure described in Safavi et al. (2019), study 1 provides an
96 identification of DDLs companies through market screening, and study 2 provides an evidence
97 analysis of published clinical studies by identified companies. This methodological approach
98 provides us with the current state of clinical validation of the top funded DDLs companies (15)
99 and is characterized by a continuous peer reviewing process to ensure reliable and credible
100 results (16).

101 **Study 1: Company Overview**

102 **Search Strategy**

103 To ascertain the globally top funded DDLS, this study combined data extraction from two
104 leading financial databases, Pitchbook and Crunchbase, augmented by supplementary web
105 searches on Google. This multi-pronged approach ensured a broad capture of the landscape,
106 identifying enterprises with significant funding aimed at dementia prevention through digital
107 lifestyle interventions. The search strategy was refined through an iterative process among the
108 co-authors, with keywords in three categories: “Verticals, methods, and industries”,
109 “Dementia”, and “Management and prevention”. Due to limited keyword search masks in
110 Crunchbase, “Dementia” and “Management and prevention” categories were merged. **S1 & S2**
111 **Tables** provide the selected search strategies and keywords used in both databases, which defer
112 due to differences in the search functions of the two databases, where Crunchbase did not utilize
113 OR/AND operators, and only predefined industries could be selected.

114 **Inclusion & Exclusion Criteria**

115 The inclusion criteria were stringently designed to focus on digital health technologies directly
116 targeting patients or consumers with interventions capable of potentially modifying lifestyle
117 factors associated with dementia risk. Essential for inclusion were technologies that
118 demonstrated a clear application towards dementia prevention, articulated through their digital
119 solutions. Exclusion criteria were carefully applied to omit companies not directly targeting
120 dementia risk, lacking in necessary detail, lacking funding information, or not providing
121 solutions in English, ensuring a focus on globally applicable and accessible services.

122 **Selection Process**

123 An intricate screening process ensued, beginning with the elimination of duplicates and a
124 thorough review of database entries and company websites. Each company was evaluated

125 against the inclusion and exclusion criteria by a dedicated researcher (JP), with a subsequent
126 independent review by a second researcher to ensure thoroughness and reliability (MN).
127 Disagreements were solved through discussion and the interrater reliability was assessed
128 through the calculation of the Cohen's kappa coefficient. This two-tiered review process was
129 augmented by expert feedback, soliciting insights from academicians and industry specialists
130 in dementia care and prevention. Experts were invited to assess the preliminary list and suggest
131 additional companies, further enriching the dataset.

132 **Data Collection**

133 Based on previous research (15), the following data points were collected via Pitchbook (as
134 available by January 30, 2023): Year founded, headquarter location, total amount raised, last
135 financing size, last financing date, last financing type, years of funding rounds, number of
136 financing rounds, number of investors and number of employees. Considered financing rounds
137 included all deal types (Angel, Seed, Early-Stage VC, Later Stage VC, Equity Crowdfunding,
138 PE Growth/Expansion, Corporate, Joint Venture, M&A) and were only included if completed
139 by January 30, 2023. In case of unavailable funding information, corresponding information
140 was retrieved from the Crunchbase database, or further from publicly available news articles to
141 identify the last financing size as indicator for the overall funding amount.

142 **Sample Characteristics**

143 The search iteration yielded a cumulative outcome of 605 total results (Pitchbook: 341,
144 Crunchbase: 262, Google: 2), and 16 duplicates were removed. The screening of the database
145 company descriptions resulted in further exclusion of 573 additional companies. Out of the
146 remaining 16 companies, funding information could not be obtained for one. In the
147 collaborative coding process according to the pre-defined set of inclusion and exclusion criteria,
148 six companies were excluded. The final list of nine companies were reviewed by four experts

149 who suggested 15 additional companies for review. On a scale of one (no expertise) to five
150 (extremely high expertise), the experts assessed their market expertise at an average score of
151 2.6. Of those 15 expert-suggested companies, two were already included from the database
152 results, and 12 were excluded in the collaborative coding process. This process provided us
153 with a list of nine companies from the database search, and one company through expert
154 feedback, resulting in a total of 10 companies (see **Figure 1**). The Cohens' kappa coefficient
155 prior to expert validation was $k_I=0.857$ (93% agreement), and after expert validation was
156 $k_E=0.66$ (86.6% agreement). These values align with a strong and moderate level of agreement
157 (17), consequently establishing the reliability of the results.

158 **[INSERT FIGURE 1 HERE]**

159 **Figure 1.** Flow diagram for the included DHIs for the prevention of dementia in the systematic
160 market analysis.

161 **Data Analysis**

162 Company data was extracted and analyzed with descriptive statistics by one researcher (JP).

163 **Study 2: Evidence Analysis**

164 **Search Strategy**

165 Peer-reviewed publications were identified by searching Google Scholar and PubMed for the
166 company name and by retrieving study references on corresponding company websites as
167 available by April 18, 2023. In case the name of the solution differed from the company name,
168 databases were searched for both names using the OR boolean operator. If necessary (due to an
169 unmanageable number of search results), Google Scholar searches were further limited through
170 the publishing date after founding year of the corresponding company and/or with the keyword
171 "Dementia" (using the AND operator), as additional search requirements.

172 **Inclusion & Exclusion Criteria**

173 Identified studies were sought to be relevant if they were peer-reviewed publications that
174 examine the potential effects of the identified solutions on clinical outcome, cost, or access to
175 care in dementia care or dementia prevention (15). Exclusions were made for studies on non-
176 dementia conditions (e.g., Parkinson's disease), non-risk groups (e.g., healthy individuals), non-
177 English publications, protocols, proof-of-concept works, systematic reviews, or commentaries,
178 due to their irrelevance for dementia prevention.

179 **Selection Process**

180 After the removal of duplicates, title and abstract screening of publications was conducted by
181 one author (JP), and full-text review was conducted by two authors (JP and MN). In case of
182 disagreements, consensus was achieved through discussion. Interrater reliability was again
183 assessed through the calculation of the Cohen's kappa.

184 **Data Collection**

185 In line with the procedure described in (15), publications were analyzed for evidence level, the
186 number of clinical subjects, the purpose of the study, target condition or risk factor (if
187 specifically targeted), and the demonstrated effect as per U.S. Preventive Services Task Force
188 (USPSTF). USPSTF levels of evidence are: Level 1 (good) with at least one randomized trial,
189 Level 2 (fair) includes non-randomized or well-designed studies, and Level 3 (poor) consists of
190 expert opinions or descriptive studies (15).

191 The purpose of this categorization was to classify studies as: effectiveness, validation, or other
192 studies. In the coding process, the journal and paper type, trial registration, and demonstrated
193 changes in utilized proxies were retrieved in addition to the data from prior research (15).
194 Moreover, on a scale of 1 (low) to five (high), subjective quality assessment scores (referring
195 to the relevance for answering the research question), were assigned to each study.

196 **Sample Characteristics**

197 1,890 publications were identified from database search. After removing 129 duplicates, 1,784
198 unique articles underwent title and abstract screening. 1,693 articles were excluded based on
199 the inclusion and exclusion criteria. After full-text review, 82 articles were further excluded,
200 for instance, due to a missing relation to the identified companies or products (n=23), systematic
201 reviews (n=19), or missing focus on dementia (n=13). Nine articles were deemed eligible for
202 evaluation of clinical evidence (see **Figure 2**). A Cohens' kappa coefficient of $k_0=1$ was
203 determined during the full-text review, while the following coding-based analysis led to an
204 initial $k_1=0.57$ (77% agreement) and a $k_2=1$ (100% agreement) after discussion.

205 **[INSERT FIGURE 2 HERE]**

206 **Figure 2.** Flow diagram for the included publications in the evaluation of clinical evidence.

207 **Data Analysis**

208 Data extraction and analysis was conducted by two authors (JP, MN) and followed a one-cycle
209 coding process based on previously introduced publication-related aspects (15). In case of
210 disagreement, consensus was reached through discussion and interrater reliability was reported.

211 **Results**

212 **Top Funded Digital Health Technology Companies Offering Dementia** 213 **Preventive Lifestyle Services**

214 The systematic search and rigorous selection process culminated in identifying 10 DDLS
215 companies (cf. **Table 1**), collectively amassing EUR 128.52 million in funding. This
216 remarkable funding concentration, predominantly within three companies (more than 75% of
217 the total funding), underscores the competitive and uneven landscape of digital dementia
218 prevention initiatives. The diversity in the years of establishment among these companies

219 highlights an evolving field (i.e., 1999 – 2021), with both longstanding entities and new entrants
220 driving innovation in dementia preventive services.

221 Geographical analysis revealed a significant European presence among the top-funded
222 companies, alongside notable representations from North America and Asia. This geographical
223 distribution emphasizes the global interest in digital solutions for dementia prevention,
224 transcending regional boundaries to address a universal public health challenge. **Table 1**
225 provides a summary of the 10 identified DDLS companies.

226 **Table 1.** List of all identified solutions that correspond with the pre-defined set of inclusion/exclusion criteria.
227 (Extracted company and funding data is per January 30, 2023).

#	Company	Year founded	Total number of employees	Total funding (mEUR)	Year of last funding
1	Neurotrack	2012	41	50.21	2022
2	Constant Therapy Health	2013	19	29.35	2017
3	NeuroNation	2011	25	19.06	2021
4	Emogoc	2021	30	13.31	2022
5	Cognifit	1999	55	6.21	2022
6	Five Lives	2019	36	6.18	2022
7	MindStep	2017	25	3.31	-**
8	Luci	2017	25	>= 0.47*	-**
9	OptiChroniX	2019	7	0.32	2022
10	Beynex	2020	6	0.1	2023
	Average	2015	27	12.85	2021

228 *Note: *Unable to retrieve total funding information, thus it is possible that the overall funding is higher; **No*
229 *information regarding last funding round available*

230 A deeper dive into the business models and funding mechanisms of these entities revealed a
231 rich tapestry of strategies aimed at sustainability and growth. Direct-to-patient models emerged
232 as a prevalent approach, reflecting a direct engagement strategy with end-users. However, the

233 pursuit of insurance reimbursements, partnerships with insurers, and the ambition for
234 governmental collaborations indicate a nuanced approach towards securing a broad base of
235 support and legitimacy. Moreover, the strategic utilization of aggregated data for research
236 signifies a forward-thinking approach to creating value beyond direct service provision.

237 The intervention strategies deployed by these companies exhibited a keen focus on cognitive
238 engagement, aligning with contemporary understanding of lifestyle factors in dementia risk.
239 However, the breadth of interventions varied, with some companies offering comprehensive
240 platforms that address multiple lifestyle domains, demonstrating a holistic approach to
241 dementia prevention. The integration of clinical insights and customizable treatment plans
242 underscored a trend towards personalized, patient-centric services, enhancing the potential
243 impact of these digital interventions.

244 **Evidence Analysis**

245 The analysis of nine publications revealed a skewed distribution of evidence across three
246 companies: Cognifit (five publications), Beynex, and Constant Therapy Health (two each). This
247 indicates that 7 out of 10 identified DDLS provided no evidence meeting our criteria. No direct
248 link was found between a company's funding and its number of relevant publications. Despite
249 Constant Therapy Health's significant funding (EUR 29.3 million), it did not lead in publication
250 count, while Beynex, with only EUR 0.1 million in funding, matched its output.

251 The publication dates of studies ranged from 2013-2022. Eight studies were published as papers
252 in journals and one as a poster presentation at a conference. Five publications are indexed in
253 PubMed and six are published in papers with an assigned journal impact score (JIS). With an
254 average JIS of 4.29, the lowest journal had a JIS of 2.31 and the highest 6.591. Three of the
255 studies were officially registered trials, and three others were IRB approved and/or a published
256 study protocol.

257 Out of nine studies, five did not fit the Clinical Effectiveness or Validation categories as
258 previously defined (15), including three feasibility studies and two comparing interventions in
259 tailored vs. untailored settings. Three studies aimed at clinical outcomes, focusing on clinical
260 outcomes, and one validated outcomes against another solution. Seven publications showed
261 level 1 evidence according to the criteria of the USPSTF, meaning that evidence was generated
262 through at least one randomized-controlled trial. Out of all the publications, only one
263 demonstrated level 2 evidence, while another publication presented level 3 evidence.

264 Average participation was n=59, ranging from n=2 to n=122, with most studies (7 out of 9)
265 involving n<100 participants. Six of the studies targeted a study population with a condition
266 and only two targeted participants with a disease risk factor. The most common targeted
267 condition was Subjective Mild Cognitive Impairment (SMCI) and Mild Cognitive Impairment
268 (MCI) itself, followed by dementia, primarily encompassing Alzheimer's disease (AD). The
269 two targeted risk factors included diabetes and old age. None of the studies demonstrated any
270 change in the targeted condition or risk factor.

271 Except for 1 study, all studies demonstrated shifts in study proxies, mainly showing improved
272 cognitive and memory functions (see **Table 2**). Overall, the quality of the analyzed publications
273 was assessed as rather mediocre with an average subjective quality score of 3.

274 **Table 2.** List of all included publications that correspond with the pre-defined set of inclusion/exclusion criteria. Different coloring represents company affiliation of study.

#	Company	Reference	Purpose	# clinical subjects	Condition / risk factor targeted	Change in incidence	Change in proxy	Level of evidence	Publication quality
1	Beynex	(18)	Clinical effectiveness	120	– AD – Subjective memory complaint	No	Improved MoCA scores Bayer-ADL scores indicated improvement in ADL.	1	1
2	Beynex	(19)	Clinical effectiveness	60	Subjective CI	No	Improved memory related cognitive parameters	1	1
3	Cognifit	(20)	Other (Tailored / untailored setting for subjects & self-efficacy / no self-efficacy)	84	Diabetes	No	Improved global cognition and memory composite scores	1	4
4	Cognifit	(21)	Other (Tailored / untailored setting for subjects)	44	– MCI – MrNPS	No	Improved performance on composite measures of global cognition, learning, delayed episodic memory	1	4
5	Cognifit	(22)	Validation	47	CI	No	Improved performance of global cognition, working memory, divided attention, processing speed	1	4
6	Cognifit	(23)	Other (feasibility combined with effectiveness)	18	– Episodic memory dysfunction – MCI	No	Improved working memory and speed	2	3
7	Cognifit	(24)	Clinical effectiveness	122	Old age	No	Improved visual-spatial information processing, visual scanning, global visual memory, naming, hand-eye coordination, visuospatial learning, and visuospatial working memory	1	5
8	Constant Therapy	(25)	Other (feasibility)	2	Dementia	No	No	3	2
9	Constant Therapy	(26)	Other (feasibility)	19	AD	No	Improved visual & auditory memory, attention, arithmetic, processing speed, adaptability	1	3
			Average	59					3

275 **Discussion**

276 The aim of this work was to not only identify the globally top-funded DDLS but to also analyze
277 the corresponding body of published clinical evidence. 10 companies with a total funding of
278 EUR 128.52 million, headquartered in eight different countries have been identified. Funding
279 ranged from EUR 0.1 million to EUR 50.21 million, with the top two companies accounting
280 for over half of the total funding. No clear correlation between a company's founding year and
281 its funding was found.

282 Clinical evidence meeting our criteria was scarce, with only nine studies from three companies
283 found. Many studies did not focus on clinical effectiveness or validation, three focused on
284 feasibility, three on clinical effectiveness, and one on validation against alternatives. Most
285 studies involved subjects with MCI or AD, with only two targeting subjects at risk. While 78%
286 of the studies used randomized-controlled trials, sample sizes were small, and findings mainly
287 showed changes in proxies rather than direct impacts on targeted conditions.

288 **Interpretation of Results**

289 **Companies offering DDLS**

290 The aging global population is making the social and economic impacts of dementia
291 increasingly severe, with the WHO highlighting the urgency of prevention through lifestyle
292 changes (1,11), and the provision of digital health interventions (DHIs) could significantly
293 contribute to those efforts. Despite this, DHIs for dementia prevention seem underfunded
294 compared to other areas, such as depression DHIs, which received more funding for the fifth-
295 best funded initiative than all analyzed dementia companies combined (27). The impression of
296 low overall funding of DDLS companies is confirmed when considering the staggering USD
297 23,796 estimated global societal cost of dementia per person with dementia in 2019 (28).

298 Since the underlying reasons for those findings are beyond the scope of this study, it should
299 rather briefly be touched upon potential causes: A potential explanation are the relatively young
300 medical findings that set the foundation for the offered interventions. A landmark study showed
301 the positive impact of a multi-domain lifestyle intervention on dementia risk in 2015 and thus
302 is not much older than a major part of the identified companies (29). On the other side, however,
303 many of the identified companies strongly leverage brain games as a way to foster cognitive
304 engagement. The idea of utilizing cognitive training to prevent or delay dementia has been
305 widely discussed before (30–33). The companies' recent establishment may explain the modest
306 funding levels, challenging the assumption that funding correlates with company age.
307 Monetization uncertainties and the prevalence of local champions, suggesting a fragmented
308 market with limited global commercial potential, could also impact funding. These hypotheses
309 underscore the need for further research in this area.

310 **Clinical Evidence**

311 The limited number of publications meeting our criteria, primarily from just three companies,
312 is unexpected. This is particularly striking considering the companies' professed strong
313 scientific orientation and their extensive citation of scientific papers on their websites (34–39).
314 Besides the challenging application of traditional evidence generation methods in Digital
315 Health (40), a potential reason for this could be the relatively low funding of the identified
316 companies since the conducting of clinical studies is associated with substantial financial costs
317 (41). Despite Beynex's low financing, it managed to produce two eligible studies, indicating no
318 strong link between a company's funding and its research output, aligning with previous
319 research findings (27). The lack of publications may also be due to the young age of the
320 companies. Many studies are still underway and unpublished. This could also explain why some
321 solutions are preliminarily accepted for insurance reimbursement, like NeuroNation, without
322 meeting the eligibility criteria. Finally, the drive for clinical research may be influenced by

323 companies' revenue models: As a large proportion of solutions are also directly targeted at
324 uninformed patients through marketing and sales activities, trials may be less demanded from
325 a target audience perspective.

326 The prominence of companies focusing on cognitive engagement through brain exercises
327 (Constant Therapy Health, Cognifit, Beynex) in our findings is notable. Brain training has been
328 a significant research focus, making it more probable for these solutions to have accumulated
329 evidence. Cognifit, the oldest company (founded in 1999), leads with five publications,
330 including two from 2013 (42). However, the newer companies, founded in 2013 (i.e., Constant
331 Therapy Health) and 2020 (i.e., Beynex), along with the more recent average publication year
332 of 2020 for remaining studies, suggest another reason for this trend. By requiring subjects to
333 perform only game-based brain training with relatively little effort (compared to changing diet
334 and exercise habits), drop-out rates could be lower, adherence rates higher, the trial more
335 manageable and short-term effects potentially faster to detect. Thus, the failure rate of those
336 studies is lower (43) and the overall risk due to extensive existing research diminished.

337 The evidence quality from the limited publications is mediocre, with most studies using
338 randomized-controlled trials (evidence level 1 according to previously determined research
339 (15), but involving small groups and showing changes only in utilized proxies. Solutions aimed
340 at reducing the risk of MCI progressing to AD targeted subjects with MCI but only showed
341 improved cognitive performance, not prevention of conversion. A potential reason for this
342 could be the additional financial and non-financial resources necessary to conduct longitudinal
343 studies at a large-scale.

344 The low number of scientific studies and identified methodological issues are in line with
345 previous findings (44), where researchers systematically analyzed clinical evidence of mobile
346 health solutions for people suffering from dementia and their relatives. On this basis, it was

347 concluded that there is no evidence for the clinical effectiveness of the analyzed solutions (44).
348 Considering the few publications and their methodological limitations, this work suggests an
349 insufficiency of evidence for the effectiveness of top funded global DDLS.

350 **Theoretical Contributions**

351 Overall, the results align with the complex definitions found in existing literature. Despite clear
352 theoretical guidelines for analysis, comparing services highlights blurred distinctions between
353 terms. Notably, a managerial aspect supports clinicians with non-clinical tasks, such as
354 documentation, following the Digital Medicine Society (DiMe)'s framework (45). This
355 indicates that digital health components can be part of digital medicine offerings, challenging
356 the clear differentiation suggested by initial terminology. This relates to strategies like those of
357 Constant Therapy Health and Cognifit, which aim to integrate into existing care processes rather
358 than just complement them, raising questions about the adequacy of assumed definitions and
359 the potential need for new concepts.

360 The foundation of DHIs is notably their evidence base. The results of the systematic review
361 found that evidence supporting identified DDLS is scarce, with many companies focusing on
362 general reviews rather than assessing their products' clinical effectiveness or comparing them
363 to other interventions. This highlights a need for more precise definitions within DHI and
364 Digital Medicine fields. While it is challenging to reclassify these solutions as merely lifestyle
365 or wellness apps without medical relevance, the current definitional framework lacks
366 specificity. A more holistic approach to classification is suggested, one that not only evaluates
367 evidence but also considers business models, offering a broader perspective on DHIs' role and
368 impact. In addition to the previously mentioned benefits of clarity of definitions, this could also
369 further strengthen the bridge between the role of evidence generation and business model
370 building and scaling in digital health: When digital medicine companies operate at the

371 crossroads between regular technology companies and pharmaceutical companies, obtaining
372 clinical evidence is paramount (46).

373 **Clinical Implications**

374 The current manuscript undertakes a critical exploration into the realm of DDLS, scrutinizing
375 the clinical evidence that underpins these emerging interventions. This inquiry is paramount,
376 not only due to the growing investments and interest in DHIs aimed at staving off dementia but
377 also because it addresses a significant gap in existing literature. The pressing need for effective
378 dementia prevention strategies, in the absence of disease-modifying treatments, underscores the
379 importance of this study.

380 Evaluating the relevance and novelty of this research, it becomes evident that it fills an essential
381 void by systematically identifying and analyzing the top funded companies within the DDLS
382 domain. This approach not only sheds light on the current landscape of digital interventions but
383 also critically assesses the extent and quality of clinical evidence supporting their efficacy. In
384 doing so, the study brings forth new perspectives on the role of digital health in preventing
385 dementia, challenging existing paradigms by questioning the robustness of the purported
386 benefits of these interventions.

387 The study's findings on the limited clinical evidence supporting the efficacy of DDLS highlight
388 the urgent need for more rigorous and longitudinal research in this area. Such evidence is crucial
389 for informing clinical guidelines, shaping public health policies, and guiding future research
390 directions. The identification of this gap not only signals the necessity for further empirical
391 inquiry but also posits the manuscript as a cornerstone for subsequent investigations aimed at
392 validating and enhancing the clinical utility of digital interventions for dementia prevention.

393 Moreover, the interdisciplinary nature of the manuscript, which intersects medical science,
394 digital technology, and health policy, exemplifies the complex and multifaceted approach
395 required to tackle dementia prevention. The manuscript's exploration of the funding dynamics
396 and the technological underpinnings of the DDLS, coupled with its analysis of clinical
397 evidence, reflects a comprehensive understanding of the ecosystem surrounding DHIs for
398 dementia. This interdisciplinary perspective is vital for devising holistic and effective
399 prevention strategies that can be seamlessly integrated into public health frameworks and
400 clinical practice.

401 The manuscript also acknowledges the paramount importance of patient and public
402 involvement in the research and development of DDLS. This recognition aligns with
403 contemporary research ethics, emphasizing the co-creation of health interventions that are not
404 only scientifically sound but also resonate with the needs, preferences, and realities of those
405 they aim to serve. Such an approach not only enhances the relevance and applicability of
406 research findings but also ensures that digital health interventions are grounded in the lived
407 experiences of individuals at risk of dementia, thereby maximizing their potential impact.

408 Lastly, the manuscript's call for transparency and availability of data is a testament to its
409 commitment to the principles of open science. By advocating for the unrestricted sharing of
410 research data and methodologies, the study sets a standard for future research in the field,
411 facilitating the replication and validation of findings, and fostering a collaborative research
412 environment that accelerates the advancement of knowledge and the development of effective
413 dementia prevention strategies.

414 In summary, the clinical implications of this manuscript extend beyond the mere analysis of
415 current DDLS. It lays the groundwork for future research, encourages interdisciplinary
416 collaboration, and underscores the importance of patient and public involvement in the creation

417 of DHIs. Furthermore, it champions the principles of transparency and open science, essential
418 for the robust, ethical, and impactful advancement of dementia prevention research.

419 **Limitations**

420 One limitation of the global market analysis is its focus on English-language solutions,
421 excluding companies targeting non-English markets, potentially overlooking well-funded
422 entities. Additionally, only companies with publicly available funding information were
423 analyzed, possibly omitting other significant players. Data completeness also affects the
424 accuracy of funding-based rankings, as market intelligence databases may not have full funding
425 details.

426 The publication analysis has two main limitations in relation to our second research question.
427 Firstly, strict inclusion and exclusion criteria meant that studies on assessment/or diagnostic
428 tools and those not focused on dementia prevention were excluded, possibly indicating a lack
429 of clinical evidence for the companies reviewed. Second, while study duration was considered,
430 the specific length of interventions wasn't, leaving some potential explanations unexplored.
431 Finally, our analysis did not compare the clinical effectiveness of the solutions directly but
432 evaluated the quality and results of each study independently, without comparing them to one
433 another.

434 **Suggestions for Future Research**

435 Despite the promising strides in developing and funding DDLS, the study highlighted a critical
436 gap in the clinical evidence underpinning these interventions. The limited scope of published
437 studies, small participant groups, and the absence of longitudinal research point to an emergent
438 field still grappling with establishing a robust evidence base. The disconnect between the
439 proliferation of funded initiatives and the paucity of rigorous clinical validation underscores the

440 nascent stage of digital interventions in dementia prevention, marking a crucial area for future
441 research and development.

442 Avenues for further research also include the screening of the global landscape with a focus on
443 local champions, since the identification process showed that there are several highly interesting
444 solutions which are only offered in a local language and setting. This research may open new
445 possibilities for studying the blending of lifestyle interventions into local surroundings like
446 hiking areas (physical activity) or community clubs (cognitive engagement). This could
447 significantly contribute to the development of best practice reference models in the field of
448 clinical evaluation itself as well as company building and business model development as a
449 whole.

450 **Acknowledgements**

451 A substantial part of work has been conducted by JP as part of his master's thesis at the
452 University of St. Gallen.

453 **Conflict of interest**

454 RV, PH, TK, and MN are affiliated with the Centre for Digital Health Interventions (CDHI), a
455 joint initiative of the Institute for Implementation Science in Health Care, University of
456 Zurich, the Department of Management, Technology, and Economics at the ETH Zurich, and
457 the institute of Technology Management and School of Medicine at the University of St.
458 Gallen. CDHI is funded in part by CSS, a Swiss health insurer, Mavie Next, an Austrian
459 healthcare provider and MTIP, a Swiss investor company. TK is also a co-founder of
460 Pathmate Technologies, a university spin-off company that creates and delivers digital clinical
461 pathways. However, neither CSS nor Pathmate Technologies, Mavie Next, or MTIP was
462 involved in this research. All other authors declare no conflict of interest.

463 **References**

- 464 1. World Health Organization. Global status report on the public health response to
465 dementia [Internet]. 2021 [cited 2024 Mar 13]. Available from:
466 <https://www.who.int/publications/i/item/9789240033245>
- 467 2. Zhu CW, Cosentino S, Ornstein K, Gu Y, Andrews H, Stern Y. Use and cost of
468 hospitalization in dementia: longitudinal results from a community-based study.
469 *Int J Geriatr Psychiatry*. 2015 Aug 29;30(8):833–41.
- 470 3. Mahoney R, Regan C, Katona C, Livingston G. Anxiety and Depression in Family
471 Caregivers of People With Alzheimer Disease: The LASER-AD Study. *The*
472 *American Journal of Geriatric Psychiatry*. 2005 Sep;13(9):795–801.
- 473 4. Xu XY, Kwan RYC, Leung AYM. Factors associated with the risk of
474 cardiovascular disease in family caregivers of people with dementia: a systematic
475 review. *Journal of International Medical Research*. 2020 Jan
476 22;48(1):030006051984547.
- 477 5. World Health Organization. Global strategy on human resources for health:
478 Workforce 2030 [Internet]. 2016 [cited 2024 Mar 13]. Available from:
479 [https://apps.who.int/iris/bitstream/handle/10665/250368/9789241511131-](https://apps.who.int/iris/bitstream/handle/10665/250368/9789241511131-eng.pdf)
480 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/250368/9789241511131-eng.pdf)

- 481 6. Gentili A, Failla G, Melnyk A, Puleo V, Tanna GL Di, Ricciardi W, et al. The cost-
482 effectiveness of digital health interventions: A systematic review of the literature.
483 Front Public Health. 2022 Aug 11;10.
- 484 7. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the
485 evidence on modifiable risk factors for cognitive decline and dementia: A
486 population-based perspective. *Alzheimer's & Dementia*. 2015 Jun 31;11(6):718–
487 26.
- 488 8. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al.
489 Dementia prevention, intervention, and care: 2020 report of the Lancet
490 Commission. *The Lancet* [Internet]. 2020 Aug 8 [cited 2024 Mar
491 27];396(10248):413–46. Available from:
492 <http://www.thelancet.com/article/S0140673620303676/fulltext>
- 493 9. Veronese N, Soysal P, Demurtas J, Solmi M, Bruyère O, Christodoulou N, et al.
494 Physical activity and exercise for the prevention and management of mild
495 cognitive impairment and dementia: a collaborative international guideline. *Eur*
496 *Geriatr Med* [Internet]. 2023 Oct 1 [cited 2024 Mar 27];14(5):925. Available from:
497 </pmc/articles/PMC10587099/>
- 498 10. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary
499 prevention of Alzheimer's disease: an analysis of population-based data. *Lancet*
500 *Neurol*. 2014 Aug;13(8):788–94.
- 501 11. World Health Organisation. Global action plan on the public health response to
502 dementia [Internet]. 2017 [cited 2023 Jul 14]. Available from:
503 [https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-](https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025)
504 [response-to-dementia-2017---2025](https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025)
- 505 12. World Health Organization. WHO guideline: recommendations on digital
506 interventions for health system strengthening [Internet]. 2019 [cited 2024 Mar 13].
507 Available from: <https://www.who.int/publications/i/item/9789241550505>
- 508 13. Jacobson N, Kowatsch T, Marsch L, editors. *Digital Therapeutics for Mental*
509 *Health and Addiction*. 1st ed. Elsevier, Academic Press; 2023.
- 510 14. Kowatsch T, Fleisch E. *Digital Health Interventions*. In: *Connected Business*.
511 Cham: Springer International Publishing; 2021. p. 71–95.

- 512 15. Safavi K, Mathews SC, Bates DW, Dorsey ER, Cohen AB. Top-Funded Digital
513 Health Companies And Their Impact On High-Burden, High-Cost Conditions.
514 Health Aff. 2019 Jan;38(1):115–23.
- 515 16. Janesick VJ. Peer Debriefing. In: The Blackwell Encyclopedia of Sociology.
516 Wiley; 2015.
- 517 17. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
518 2012;22(3):276–82.
- 519 18. Çınar N, Sahiner TAH. Effects of the online computerized cognitive training
520 program BEYNEX on the cognitive tests of individuals with subjective cognitive
521 impairment and Alzheimer’s disease on rivastigmine therapy. Turk J Med Sci
522 [Internet]. 2020 Jan 1 [cited 2024 Mar 26];50(1):231–8. Available from:
523 <https://journals.tubitak.gov.tr/medical/vol50/iss1/31>
- 524 19. Sahiner TAH, Cınar N. TD-P-002: EFFECTS OF ONLINE COMPUTERIZED
525 COGNITIVE TRAINING PROGRAM BEYNEX ON THE COGNITIVE TESTS OF
526 INDIVIDUALS WITH SUBJECTIVE COGNITIVE IMPAIRMENT (SCI).
527 Alzheimer’s & Dementia [Internet]. 2018 Jul 1 [cited 2024 Mar
528 26];14(7S_Part_3):P186–P186. Available from:
529 <https://onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2018.06.2018>
- 530 20. Bahar-Fuchs A, Barendse MEA, Bloom R, Ravona-Springer R, Heymann A,
531 Dabush H, et al. Computerized Cognitive Training for Older Adults at Higher
532 Dementia Risk due to Diabetes: Findings From a Randomized Controlled Trial.
533 The Journals of Gerontology: Series A [Internet]. 2020 Mar 9 [cited 2024 Mar
534 26];75(4):747–54. Available from: <https://dx.doi.org/10.1093/gerona/glz073>
- 535 21. Bahar-Fuchs A, Webb S, Bartsch L, Clare L, Rebok G, Cherbuin N, et al. Tailored
536 and Adaptive Computerized Cognitive Training in Older Adults at Risk for
537 Dementia: A Randomized Controlled Trial. Journal of Alzheimer’s Disease. 2017
538 Jan 1;60(3):889–911.
- 539 22. Embon-Magal S, Krasovsky T, Doron I, Asraf K, Haimov I, Gil E, et al. The effect
540 of co-dependent (thinking in motion [TIM]) versus single-modality (CogniFit)
541 interventions on cognition and gait among community-dwelling older adults with
542 cognitive impairment: a randomized controlled study. BMC Geriatr [Internet].
543 2022 Aug 31 [cited 2024 Mar 26];22(1):720. Available from:
544 <https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-022-03403-x>

- 545 23. Gigle KL, Blomeke K, Shatil E, Weintraub S, Reber PJ. Preliminary evidence for
546 the feasibility of at-home online cognitive training with older adults.
547 *Gerontechnology*. 2013;12(1):26–35.
- 548 24. Shatil E. Does combined cognitive training and physical activity training enhance
549 cognitive abilities more than either alone? A four-condition randomized controlled
550 trial among healthy older adults. *Front Aging Neurosci*. 2013 Mar
551 26;5(MAR):41237.
- 552 25. Edgar DL, Bargmann PL. Clinical Study of the Effectiveness of Constant Therapy
553 in the Treatment of Clients With Dementia: Implications for Telepractice. *Perspect*
554 *ASHA Spec Interest Groups* [Internet]. 2021 Jun 7 [cited 2024 Mar 26];6(3):691–
555 703. Available from: https://pubs.asha.org/doi/10.1044/2021_PERSP-20-00123
- 556 26. Marin A, DeCaro R, Schiloski K, Elshaar A, Dwyer B, Vives-Rodriguez A, et al.
557 Home-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease:
558 Feasibility Randomized Controlled Trial. *JMIR Form Res* [Internet]. 2022 Sep 12
559 [cited 2024 Mar 26];6(9):e34450. Available from:
560 <http://www.ncbi.nlm.nih.gov/pubmed/36094804>
- 561 27. Salamanca-Sanabria A, Castro O, Alattas A, Teepe GW, Leidenberger K, Fleisch
562 E, et al. Top-Funded Companies Offering Digital Health Interventions for the
563 Prevention and Treatment of Depression: A Systematic Market Analysis
564 (Preprint). *JMIR Preprints*. 2022;
- 565 28. Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The
566 worldwide costs of dementia in 2019. *Alzheimer's & Dementia*. 2023 Jul
567 8;19(7):2865–73.
- 568 29. Ngandu T, Lehtisalo J, Solomon A, Levälähti E, Ahtiluoto S, Antikainen R, et al.
569 A 2 year multidomain intervention of diet, exercise, cognitive training, and
570 vascular risk monitoring versus control to prevent cognitive decline in at-risk
571 elderly people (FINGER): a randomised controlled trial. *The Lancet*. 2015
572 Jun;385(9984):2255–63.
- 573 30. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation
574 for persons with mild to moderate dementia of the Alzheimer's or vascular type:
575 a review. *Alzheimers Res Ther*. 2013;5(4):35.
- 576 31. Clare L. Cognitive training and cognitive rehabilitation for people with early-stage
577 dementia. *Rev Clin Gerontol*. 2003 Feb 29;13(01).

- 578 32. Galante E, Venturini G, Fiaccadori C. Computer-based cognitive intervention for
579 dementia: preliminary results of a randomized clinical trial. *G Ital Med Lav Ergon.*
580 2007;29(3 Suppl B):B26-32.
- 581 33. Gates NJ, Sachdev PS, Fiatarone Singh MA, Valenzuela M. Cognitive and
582 memory training in adults at risk of dementia: A Systematic Review. *BMC Geriatr.*
583 2011 Dec 25;11(1):55.
- 584 34. Neurotrack. Clinical Studies on Cognitive Screening and Intervention by
585 Neurotrack [Internet]. [cited 2024 Mar 29]. Available from:
586 <https://neurotrack.com/science>
- 587 35. NeuroNation. The science behind NeuroNation [Internet]. [cited 2024 Mar 29].
588 Available from: [https://www.neuronation.com/science/en/science-behind-](https://www.neuronation.com/science/en/science-behind-neuronation/)
589 [neuronation/](https://www.neuronation.com/science/en/science-behind-neuronation/)
- 590 36. Five Lives. Behind the Science [Internet]. [cited 2024 Mar 29]. Available from:
591 <https://www.fivelives.health/science>
- 592 37. Mindsteps. Concept [Internet]. [cited 2024 Mar 29]. Available from:
593 <https://www.mindsteps.ch/konzept/>
- 594 38. Luci. Science [Internet]. [cited 2024 Mar 29]. Available from:
595 <https://lucilab.ca/en/science/>
- 596 39. OptiChroniX. Fight Alzheimer, Lifestyle Medicines, Health Coach [Internet]. [cited
597 2024 Mar 29]. Available from: <https://optichronix.com/science>
- 598 40. Guo C, Ashrafian H, Ghafur S, Fontana G, Gardner C, Prime M. Challenges for
599 the evaluation of digital health solutions—A call for innovative evidence
600 generation approaches. *NPJ Digit Med.* 2020 Aug 27;3(1):110.
- 601 41. Bentley C, Cressman S, van der Hoek K, Arts K, Dancey J, Peacock S.
602 Conducting clinical trials—costs, impacts, and the value of clinical trials networks:
603 A scoping review. *Clinical Trials.* 2019 Apr 10;16(2):183–93.
- 604 42. Simons DJ, Boot WR, Charness N, Gathercole SE, Chabris CF, Hambrick DZ, et
605 al. Do “Brain-Training” Programs Work? *Psychological Science in the Public*
606 *Interest.* 2016 Oct 2;17(3):103–86.
- 607 43. Fogel DB. Factors associated with clinical trials that fail and opportunities for
608 improving the likelihood of success: A review. *Contemp Clin Trials Commun.*
609 2018 Sep;11:156–64.

- 610 44. Zeiler M, Chmelirsch C, Dietzel N, Kolominsky-Rabas PL. Wissenschaftliche
611 Evidenz und Nutzerqualität von Mobile-Health-Anwendungen für Menschen mit
612 kognitiven Beeinträchtigungen und deren Angehörige. Z Evid Fortbild Qual
613 Gesundheitswes. 2023 Apr;177:10–7.
- 614 45. Digital Medicine Society (DiMe). Defining Digital Medicine [Internet]. [cited 2024
615 Mar 13]. Available from: [https://dimesociety.org/about-us/defining-digital-](https://dimesociety.org/about-us/defining-digital-medicine/)
616 [medicine/](https://dimesociety.org/about-us/defining-digital-medicine/)
- 617 46. Steinberg D, Horwitz G, Zohar D. Building a business model in digital medicine.
618 Nat Biotechnol. 2015 Sep 1;33(9):910–20.
- 619

620 **List of supplemental materials**

- 621 S1 Table. Search categories and keywords for the Pitchbook search.
- 622 S2 Table. Search categories and keywords for the Crunchbase search.

Figure 1:




Figure 2:

